Some Pills For Heartburn Increased The Risk Of Pneumonia – Part 1 of 3
Some Pills For Heartburn Increased The Risk Of Pneumonia. Popular heartburn drugs, including proton grill inhibitors and histamine-2 receptor antagonists, may plant the risk of pneumonia, new research finds. Researchers in Korea analyzed the results of 31 studies on heartburn drugs published between 1985 and 2009. “Our results suggest that the use of acid suppressive drugs is associated with an increased chance of pneumonia,” said Dr Sang Min Park of the department of family medicine at Seoul National University Hospital in Korea. “Patients should be guarded at overuse of acid-suppressive drugs, both high-dose and long duration”.
Sales of these enormously popular drugs – the second best-selling category of medications worldwide – reached nearly $27 billion in the United States in 2005, according to experience information in the study, published Dec 20, 2010 in CMAJ (Canadian Medical Association Journal). Proton pump inhibitors (PPIs) decrease acid production in the stomach and are used to treat heartburn, gastroesophageal reflux disease (GERD) and gastric ulcers. They include omeprazole (Prilosec), lansoprazole (Prevacid) and esomeprazole (Nexium).
Histamine-2 receptor antagonists, often called H2 blockers, use a remarkable mechanism to reduce stomach acid and include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac). According to Consumer Reports, sales of a Nexium unattended hit $4,8 billion in 2008. Yet recently, studies have raised concerns about the drugs. Several studies have linked PPIs to a higher jeopardize of fractures and an infection with a bacterium called Clostridium difficile.
Some previous studies also linked heartburn drugs to a higher risk of pneumonia, but the research has been mixed, according to the study authors. Their meta-analysis combined the results of eight observational studies that found that taking PPIs increased the chances of developing pneumonia by 27 percent, while taking H2 blockers resulted in a 22 percent increased unlooked-for of pneumonia.